Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders (QoQ) (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders (QoQ) (2009 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -403.07% |
| Sep 30, 2024 | 391.05% |
| Jun 30, 2024 | -245.15% |
| Mar 31, 2024 | 136.47% |
| Dec 31, 2023 | -232.08% |
| Sep 30, 2023 | 376.65% |
| Jun 30, 2023 | 60.39% |
| Mar 31, 2023 | 40.13% |
| Dec 31, 2022 | -594.57% |
| Sep 30, 2022 | 22.46% |
| Jun 30, 2022 | -495.83% |
| Mar 31, 2022 | 132.00% |
| Dec 31, 2021 | 73.99% |
| Sep 30, 2021 | -175.22% |
| Jun 30, 2021 | 302.10% |
| Mar 31, 2021 | 14,300,100.00% |
| Dec 31, 2020 | 60.00% |
| Sep 30, 2020 | -600.00% |
| Dec 31, 2019 | -71,999,900.00% |
| Sep 30, 2019 | 66.67% |